20
Oct

2015

GliaCure President presents at ADDF, Society for Neuroscience conferences

On October 6 GliaCure President Phil Haydon presented an invited talk at the ADDF’s 16th International Conference on Alzheimer’s Drug Discovery in New Jersey. In his presentation, titled, “The P2Y6 receptor as a therapeutic target for Alzheimer’s disease”, Phil outlined the strategy underlying the company’s approach to development of a therapy to halt disease progression in mild to moderate Alzheimer’s patients. This first public presentation of GliaCure’s preclinical program, its successful Phase 1a clinical trial in healthy volunteers and its ongoing Phase 1b clinical trial in patients, stimulated positive discussion, both of the science underlying GliaCure’s program and of the company’s ability to complete studies with an aggressive timeline. 

Phil also presented GliaCure’s research on October 17 at the annual Society for Neuroscience conference in a nanosymposium titled, “Alzheimer’s Disease: Experimental Therapeutics”. 

“My participation in the ADDF and SfN conferences this year were great experiences,” Phil Haydon said. “I was extremely encouraged by the reception of our program and look forward to sharing the results of our Phase 1b clinical program after the study is finalized later this year.” 

Funding for GliaCure’s Phase 1b clinical trial has been provided in part by the Alzheimer’s Drug Discovery Foundation. 

About GliaCure, Inc.

GliaCure is a privately held company that is pioneering the development of novel therapeutics aimed at treating neurological and neuropsychiatric disorders of the brain. The company’s approaches are based on glial targets, a cell type in the brain that has previously been overlooked in drug discovery. The dual phagocytic and anti-inflammatory actions of the GliaCure’s lead clinical candidate, GC021109, have the potential to serve as a disease-modifying treatment for Alzheimer’s disease and to affect other disorders, including asthma, psoriasis, Parkinson’s disease, multiple sclerosis and glaucoma. GliaCure has an exclusive license to the GC021109 compound and related technology from Tufts University. GliaCure also has a pipeline program for the development of therapeutics for astrocytic targets related to sleep disorders and depression. The company is based in Boston and is headed by Professor Philip G. Haydon, who also holds the position of Annetta and Gustav Grisard Professor and Chair of Neuroscience at Tufts University.

About the Alzheimer’s Drug Discovery Foundation

The ADDF catalyzes and funds drug discovery and drug development for Alzheimer’s disease and related disorders, and cognitive aging. To learn more about the ADDF, visit the website at: www.alzdiscovery.org.